Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01089023
Other study ID # ML22440
Secondary ID
Status Completed
Phase Phase 4
First received March 8, 2010
Last updated June 23, 2014
Start date January 2010
Est. completion date December 2011

Study information

Verified date June 2014
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority Qatar: Ministry of Health
Study type Interventional

Clinical Trial Summary

This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a stable dose of non-biologic disease modifying anti-rheumatic drugs (DMARD) or anti-tumor necrosis factors (TNFs). RoActemra/Actemra will be administered as a monotherapy or in combination with DMARDs. RoActemra/Actemra will be administered as intravenous infusion at a dose of 8 mg/kg every 4 weeks for a total of 6 infusions. The anticipated time on study treatment is 24 weeks. The target sample size is 50-150 patients.


Recruitment information / eligibility

Status Completed
Enrollment 95
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- adult patients, >/=18 years of age

- moderate to severe rheumatoid arthritis (DAS28 >3.2) of 6 months duration

- inadequate clinical response to non-biologic DMARDs or anti-TNF

- bodyweight </=150 kg

Exclusion Criteria:

- rheumatic autoimmune disease or inflammatory joint disease other than RA

- major surgery within 8 weeks prior to screening or planned major surgery within 6 months following screening

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
tocilizumab [RoActemra/Actemra]
8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hoffmann-La Roche

Countries where clinical trial is conducted

Bahrain,  Iran, Islamic Republic of,  Kuwait,  Qatar,  United Arab Emirates, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Reporting Any Adverse Event - Overall Summary of Events Percentage of participants with a serious adverse event (SAE), who died, with an adverse event (AE), or study drug related AE during the study. Baseline and Weeks 2, 4, 8, 12, 16, 20, and 24 No
Secondary Percentage of Participants by Disease Activity Score Based on 28-Joint Count (DAS28) Category DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hr]) and global health assessment (participant rated global assessment of disease activity using 10-mm Visual analog scale - VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A DAS28 score of greater than (>)5.1 indicated high disease activity, a score of >3.2 but less than or equal to (=)5.1 indicated moderate disease activity, a score of greater than or equal to (=)2.6 but =3.2 indicated low disease activity, and a score of less than <2.6 indicated disease remission. Week 24 is the Follow-Up visit. Baseline and Weeks 4, 8, 12, 16, 20, and 24 No
Secondary Percentage of Participants Achieving a Clinically Meaningful Improvement as Measured by DAS28 DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hr) and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants achieved a clinically meaningful improvement in DAS28 if there was a reduction of at least 1.2 units from baseline. Weeks 4, 8, 12, 16, 20, and 24 No
Secondary Time to DAS28 Response by DAS28 Category Time to response is the number of days from date of first infusion to date of event. DAS28 response was defined as achievement of Low Disease Activity (DAS28 =2.6 to =3.2), Remission (DAS28 <2.6), or Clinically Meaningful Improvement (change of >1.2 from baseline). Weeks 4, 8, 12, 16, 20, and 24 No
Secondary Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) of at Least 0.22 Units HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. Weeks 4, 8, 12, 16, 20, and 24 No
Secondary Percentage of Participants With Improvement in Physical Function by HAQ-DI Category Physical function scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3. The HAQ-DI score at every visit was categorized into none to mild disability (HAQ-DI <1), moderate disability (1= HAQ-DI <2) and severe disability (HAQ-DI =2). The percentages of the participants falling in each of these categories with respect to the visits were determined. Baseline, Weeks 4, 8, 12, 16, 20, and 24 No
Secondary HAQ-DI Score by Visit HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity. To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen. Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. Minimum score was 0, maximum score was 3.. Baseline and Weeks 4, 8, 12, 16, 20, and 24 No
Secondary C-Reactive Protein (CRP) Values by Study Visit CRP is an acute phase inflammatory marker. The serum concentration of CRP is measured in milligrams per liter (mg/L). A reduction in the level is considered an improvement. Baseline and Weeks 4, 8, 12, 16, 20, and 24 No
Secondary Erythrocyte Sedimentation Rate ESR (measured in mm/hr) is an inflammation marker used to determine acute phase response. Baseline and Weeks 4, 8, 12, 16, 20, and 24 No
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4